Skip to main content

Table 3 Potential drug-drug and drug-disease interactions

From: Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City

Interactions

Patients

n = 624

n (%)

Potential drug-drug interactions

492 (78.8)

Number of potential drug-drug interactions*

 

   1

154 (24.7)

   2

92 (14.7)

   3–4

154 (24.7)

   ≥ 5

92 (14.7)

Type D

24 (3.8)

   ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation)

11 (1.8)

   NSAID*+ Methotrexate

5 (0.8)

   NSAID* +anticoagulants (or glucocorticoids)

5 (0.8)

   β blocking agents + Verapamil (or Fluoxetin)

3 (0.4)

Type C

468 (75.0)

   ACE* inhibitors + NSAID*

252 (40.4)

   NSAID*+ low dose ASA*

212 (34.0)

   NSAID*+ sulfonylureas

128 (20.5)

   ACE* inhibitors + low dose ASA*

130 (20.8)

   β blocking agents + NSAID*

107 (17.1)

   NSAID* + Diuretics

105 (16.8)

   ACE* inhibitors + glybenclamide

68 (10.9)

   NSAID*+ other NSAID*

51 (8.2)

   ACE* inhibitors + thiazide diuretics

47 (7.6)

   Pravastatin + bezafibrate

35 (5.6)

   Pentoxiyilline + antihypertensives

37 (5.9)

   Metformin+ ranitidine

40 (6.5)

   Glibenclamide + antimycotics or cotrimoxazole

24 (3.9)

   Furosemide + ACE* inhibitors

21 (3.4)

   ACE* inhibitors + antiacids

19 (3.1)

   Alendronate + NSAIDs*

18 (2.9)

   Insulin + antihypertensive

18 (2.9)

   Pentoxifylline + hypoglycemic agents

14 (2.2)

   Acetaminophen + carbamazepin

14 (2.2)

   Ranitidine + azole type of antimycotics

11 (1.8)

   Others

61 (9.4)

Potential drug-disease interactions

400 (64.1)

Number of potential drug-disease interactions

 

   1

346 (55.4)

   ≥ 2

54 (8.7)

NSAIDs* in patients with hypertension and/or chronic heart failure

384 (61.5)

β blocking agents in patients with diabetes mellitus

31 (5.0)

NSAIDs* in patients with chronic renal insufficiency

18 (2.9)

NSAIDs* in patients with previous peptic ulcer

8 (1.3)

Thiazides diuretics in patients with gout

7 (1.1)

Metformin in patients with chronic renal insufficiency or congestive heart failure

6 (1.0)

β blocking agents in patients with peripheral vascular disease

4 (0.6)

β blocking agents in patients with asthma/COPD*

3 (0.5)

Others

5 (1.0)

  1. *ACE: angiotensin-converting enzyme; ASA: acetylsalicylic acid; COPD: chronic obstructive pulmonary disease; NSAID: Non-steroidal anti-inflammatory drugs.